EHElias A. Halabi

Elias A. Halabi

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Elias A. Halabi has a total of 24 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    γ‐Butyrolactone Derivatives of MSA‐2 are STING Prodrugs

    by Kelton Schleyer, Elias A. Halabi, Ralph Weissleder

    STING agonists are potent enhancers of a pro‐inflammatory response and, thus, potentially useful therapeutics. Unfortunately, many agonists developed to date require complex drug delivery formulations and often have poor water solubility, limiting their use for systemic administration. Here, we report the discovery and chemical characterization of lactones of MSA‐2 as new STING prodrugs with enhanced properties. We show that these prodrugs form efficient inclusion complexes with tumor myeloid cell targeting cyclodextrin nanoparticles and propose a new mechanism of formation and hydrolysis.


  • Open Access

    Magnetic Silica‐Coated Fluorescent Microspheres (MagSiGlow) for Simultaneous Detection of Tumor‐Associated Proteins

    by Elias A. Halabi, Isabel Gessner, Katherine S. Yang, Jae‐Jun Kim, Rupsa Jana, Hannah M. Peterson, Joshua D. Spitzberg, Ralph Weissleder

    Multiplexed bead assays for solution‐phase biosensing often encounter cross‐over reactions during signal amplification steps, leading to unwanted false positive and high background signals. Current solutions involve complex custom‐designed and costly equipment, limiting their application in simple laboratory setup. In this study, we introduce a straightforward protocol to adapt a multiplexed single‐bead assay to standard fluorescence imaging plates, enabling the simultaneous analysis of thousands of reactions per plate. This approach focuses on the design and synthesis of bright fluorescent and magnetic microspheres (MagSiGlow) with multiple fluorescent wavelengths serving as unique detection markers. The imaging‐based, single‐bead assay, combined with a scripted algorithm, allows the detection, segmentation, and co‐localization on average of 7500 microspheres per field of view across five imaging channels in less than one second. We demonstrate the effectiveness of this method with remarkable sensitivity at low protein detection limits (100 pg/mL). This technique showed over 85 % reduction in signal cross‐over to the solution‐based method after the concurrent detection of tumor‐associated protein biomarkers. This approach holds the promise of substantially enhancing high throughput biosensing for multiple targets, seamlessly integrating with rapid image analysis algorithms.


  • Open Access

    Magnetic Silica‐Coated Fluorescent Microspheres (MagSiGlow) for Simultaneous Detection of Tumor‐Associated Proteins

    by Elias A. Halabi, Isabel Gessner, Katherine S. Yang, Jae‐Jun Kim, Rupsa Jana, Hannah M. Peterson, Joshua D. Spitzberg, Ralph Weissleder

    Multiplexed bead assays for solution‐phase biosensing often encounter cross‐over reactions during signal amplification steps, leading to unwanted false positive and high background signals. Current solutions involve complex custom‐designed and costly equipment, limiting their application in simple laboratory setup. In this study, we introduce a straightforward protocol to adapt a multiplexed single‐bead assay to standard fluorescence imaging plates, enabling the simultaneous analysis of thousands of reactions per plate. This approach focuses on the design and synthesis of bright fluorescent and magnetic microspheres (MagSiGlow) with multiple fluorescent wavelengths serving as unique detection markers. The imaging‐based, single‐bead assay, combined with a scripted algorithm, allows the detection, segmentation, and co‐localization on average of 7500 microspheres per field of view across five imaging channels in less than one second. We demonstrate the effectiveness of this method with remarkable sensitivity at low protein detection limits (100 pg/mL). This technique showed over 85 % reduction in signal cross‐over to the solution‐based method after the concurrent detection of tumor‐associated protein biomarkers. This approach holds the promise of substantially enhancing high throughput biosensing for multiple targets, seamlessly integrating with rapid image analysis algorithms.


  • Open Access

    Pharmacological Polarization of Tumor‐Associated Macrophages Toward a CXCL9 Antitumor Phenotype

    by Noah Enbergs, Elias A. Halabi, Anne‐Gaëlle Goubet, Kelton Schleyer, Ina R. Fredrich, Rainer H. Kohler, Christopher S. Garris, Mikaël J. Pittet, Ralph Weissleder

    Tumor‐associated macrophages (TAM) are a diverse population of myeloid cells that are often abundant and immunosuppressive in human cancers. CXCL9 Hi TAM has recently been described to have an antitumor phenotype and is linked to immune checkpoint response. Despite the emerging understanding of the unique antitumor TAM phenotype, there is a lack of TAM‐specific therapeutics to exploit this new biological understanding. Here, the discovery and characterization of multiple small‐molecule enhancers of chemokine ligand 9 (CXCL9) and their targeted delivery in a TAM‐avid systemic nanoformulation is reported. With this strategy, it is efficient encapsulation and release of multiple drug loads that can efficiently induce CXCL9 expression in macrophages, both in vitro and in vivo in a mouse tumor model. These observations provide a window into the molecular features that define TAM‐specific states, an insight a novel therapeutic anticancer approach is used to discover.


  • Highly Active Myeloid Therapy for Cancer

    by Ina R. Fredrich, Elias A. Halabi, Rainer H. Kohler, Xinying Ge, Christopher S. Garris, Ralph Weissleder

    Tumor-associated macrophages (TAM) interact with cancer and stromal cells and are integral to sustaining many cancer-promoting features. Therapeutic manipulation of TAM could therefore improve clinical outcomes and synergize with immunotherapy and other cancer therapies. While different nanocarriers have been used to target TAM, a knowledge gap exists on which TAM pathways to target and what payloads to deliver for optimal antitumor effects. We hypothesized that a multipart combination involving the Janus tyrosine kinase (JAK), noncanonical nuclear factor kappa light chain enhancer of activated B cells (NF-κB), and toll-like receptor (TLR) pathways could lead to a highly active myeloid therapy (HAMT). Thus, we devised a screen to determine drug combinations that yield maximum IL-12 production from myeloid cells to treat the otherwise highly immunosuppressive myeloid environments in tumors. Here we show the extraordinary efficacy of a triple small-molecule combination in a TAM-targeted nanoparticle for eradicating murine tumors, jumpstarting a highly efficient antitumor response by adopting a distinctive antitumor TAM phenotype and synergizing with other immunotherapies. The HAMT therapy represents a recently developed approach in immunotherapy and leads to durable responses in murine cancer models.


  • Open Access

    Hybrid LNP Prime Dendritic Cells for Nucleotide Delivery

    by Riddha Das, Elias A. Halabi, Ina R. Fredrich, Juhyun Oh, Hannah M. Peterson, Xinying Ge, Ella Scott, Rainer H. Kohler, Christopher S. Garris, Ralph Weissleder

    The efficient activation of professional antigen‐presenting cells—such as dendritic cells (DC)—in tumors and lymph nodes is critical for the design of next‐generation cancer vaccines and may be able to provide anti‐tumor effects by itself through immune stimulation. The challenge is to stimulate these cells without causing excessive toxicity. It is hypothesized that a multi‐pronged combinatorial approach to DC stimulation would allow dose reductions of innate immune receptor‐stimulating TLR3 agonists while enhancing drug efficacy. Here, a hybrid lipid nanoparticle (LNP) platform is developed and tested for double‐stranded RNA (polyinosinic:polycytidylic acid for TLR3 agonism) and immune modulator (L‐CANDI) delivery. This study shows that the ≈120 nm hybrid nanoparticles‐in‐nanoparticles effectively eradicate tumors by themselves and generate long‐lasting, durable anti‐tumor immunity in mouse models.


  • Light-Deactivated Fluorescent Probes (FLASH-Off) for Multiplexed Imaging

    by Elias A. Halabi, Ralph Weissleder

    Highly multiplexed, cyclic fluorescence imaging has advanced our understanding of the biology, evolution, and complexity of human diseases. Currently available cyclic methods still have considerable limitations including the need for long quenching times and extensive wash steps. Here, we report a new series of fluorochromes that can be efficiently inactivated by a single light pulse (∼405 nm) by means of a photo-immolating triazene linker. Upon UV-light irradiation, the rhodamines are cleaved off from the antibody conjugates and undergo a fast intramolecular spirocyclization that inherently switches off their fluorescence emission without the need to wash or add exogenous chemicals. We show that these switch-off probes are fast, highly controllable, biocompatible, and allow spatiotemporal quenching control of live and fixed samples.


  • Open Access

    Dual Immunostimulatory Pathway Agonism through a Synthetic Nanocarrier Triggers Robust Anti‐Tumor Immunity in Murine Glioblastoma

    by Sophie Lugani, Elias A. Halabi, Juhyun Oh, Rainer H. Kohler, Hannah M. Peterson, Xandra O. Breakefield, E. Antonio A. Chiocca, Miles A. Miller, Christopher S. Garris, Ralph Weissleder

    Myeloid cells are abundant, create a highly immunosuppressive environment in glioblastoma (GBM), and thus contribute to poor immunotherapy responses. Based on the hypothesis that small molecules can be used to stimulate myeloid cells to elicit anti‐tumor effector functions, a synthetic nanoparticle approach is developed to deliver dual NF‐kB pathway‐inducing agents into these cells via systemic administration. Synthetic, cyclodextrin‐adjuvant nanoconstructs (CANDI) with high affinity for tumor‐associated myeloid cells are dually loaded with a TLR7 and 8 (Toll‐like receptor, 7 and 8) agonist (R848) and a cIAP (cellular inhibitor of apoptosis protein) inhibitor (LCL‐161) to dually activate these myeloid cells. Here CANDI is shown to: i) readily enter the GBM tumor microenvironment (TME) and accumulate at high concentrations, ii) is taken up by tumor‐associated myeloid cells, iii) potently synergize payloads compared to monotherapy, iv) activate myeloid cells, v) fosters a “hot” TME with high levels of T effector cells, and vi) controls the growth of murine GBM as mono‐ and combination therapies with anti‐PD1. Multi‐pathway targeted myeloid stimulation via the CANDI platform can efficiently drive anti‐tumor immunity in GBM.